Lantheus (LNTH) Rating Lowered to Hold at BidaskClub

BidaskClub downgraded shares of Lantheus (NASDAQ:LNTH) from a buy rating to a hold rating in a report released on Thursday.

LNTH has been the topic of several other reports. Zacks Investment Research cut Lantheus from a buy rating to a hold rating in a research report on Wednesday, January 17th. Jefferies Group reaffirmed a buy rating and issued a $22.00 price objective on shares of Lantheus in a research note on Thursday, October 12th. ValuEngine raised Lantheus from a hold rating to a buy rating in a research note on Saturday, February 3rd. Credit Suisse Group raised their price objective on Lantheus from $19.00 to $23.00 and gave the stock a neutral rating in a research note on Friday, November 3rd. Finally, Wells Fargo & Co raised Lantheus from a market perform rating to an outperform rating in a research note on Thursday, November 2nd. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus target price of $24.75.

Lantheus (NASDAQ:LNTH) traded down $0.70 during trading on Thursday, hitting $19.00. The company had a trading volume of 99,309 shares, compared to its average volume of 284,815. The company has a debt-to-equity ratio of -3.41, a current ratio of 2.96 and a quick ratio of 2.46. Lantheus has a 12 month low of $9.00 and a 12 month high of $24.45. The stock has a market capitalization of $755.75, a PE ratio of 24.44, a PEG ratio of 1.31 and a beta of 0.95.

In related news, insider Michael P. Duffy sold 11,917 shares of Lantheus stock in a transaction that occurred on Tuesday, November 14th. The stock was sold at an average price of $21.63, for a total transaction of $257,764.71. Following the sale, the insider now owns 152,301 shares of the company’s stock, valued at approximately $3,294,270.63. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Timothy G. Healey sold 11,314 shares of Lantheus stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $21.51, for a total value of $243,364.14. The disclosure for this sale can be found here. Insiders have sold a total of 48,752 shares of company stock worth $1,077,129 in the last three months. 2.30% of the stock is owned by corporate insiders.

Large investors have recently added to or reduced their stakes in the business. Sei Investments Co. increased its stake in Lantheus by 189.6% in the 3rd quarter. Sei Investments Co. now owns 7,829 shares of the medical equipment provider’s stock worth $139,000 after acquiring an additional 5,126 shares during the last quarter. Bank of Montreal Can raised its position in shares of Lantheus by 371.6% in the 4th quarter. Bank of Montreal Can now owns 6,819 shares of the medical equipment provider’s stock worth $139,000 after acquiring an additional 5,373 shares in the last quarter. Teachers Retirement System of The State of Kentucky bought a new position in shares of Lantheus in the 2nd quarter worth $141,000. LS Investment Advisors LLC raised its position in shares of Lantheus by 47.1% in the 3rd quarter. LS Investment Advisors LLC now owns 9,306 shares of the medical equipment provider’s stock worth $166,000 after acquiring an additional 2,981 shares in the last quarter. Finally, Cambria Investment Management L.P. bought a new position in shares of Lantheus in the 3rd quarter worth $198,000. 91.07% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This story was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this story on another publication, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The correct version of this story can be read at https://www.com-unik.info/2018/02/09/lantheus-lnth-rating-lowered-to-hold-at-bidaskclub.html.

Lantheus Company Profile

Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit